open access publication

Article, 2024

Insulin Degludec in People with Type 2 Diabetes in China: A Non-interventional, Retrospective Chart Review Study (CN-TREAT)

Diabetes Therapy, ISSN 1869-6953, 1869-6961, Volume 15, 3, Pages 725-739, 10.1007/s13300-024-01533-6

Contributors

Wang, Weimin [1] Chang, Xiang-Yun [2] Lehrskov, Lars Lang 0000-0002-4449-671X [3] Li, Ling [4] Nordentoft, Mads [3] Quan, Jin-Xing [5] Sha, Yubo [6] Zhong, Xing [7] Yang, Caixian [8] Zhu, Da-Long (Corresponding author) [1]

Affiliations

  1. [1] Nanjing Drum Tower Hospital
    2. [NORA names: China; Asia, East];
  2. [2] Shihezi University
    3. [NORA names: China; Asia, East];
  3. [3] Novo Nordisk (Denmark)
    4. [NORA names: Novo Nordisk; Private Research; Denmark; Europe, EU; Nordic; OECD];
  4. [4] Zhongda Hospital Southeast University
    5. [NORA names: China; Asia, East];
  5. [5] Gansu Provincial Hospital
    6. [NORA names: China; Asia, East];

Abstract

IntroductionInsulin degludec (degludec), an ultra-long-acting basal insulin analogue, provides equivalent glycemic control to other basal insulin analogues, with lower risk of hypoglycemia and flexible dosing. Chinese TREsiba AudiT (CN-TREAT) investigated outcomes with degludec in people with type 2 diabetes (T2D) in routine clinical practice in China.MethodsThis was a retrospective chart review study in adults with T2D initiating or switching to degludec at 50 sites in China between January 2020 and July 2021. The primary endpoint was change in glycated hemoglobin (HbA1c) from baseline to end of study (EOS; week 20). Secondary endpoints included change from baseline to EOS in fasting plasma glucose (FPG), self-measured plasma glucose (SMPG), daily insulin dose, and rate of hypoglycemia.ResultsData from 936 participants were included (499 insulin-naïve; 437 insulin-experienced). Mean (95% confidence interval [CI]) HbA1c change from baseline to EOS was − 1.48%-points (− 1.57; − 1.38; P < 0.0001) overall: − 1.95%-points (− 2.08; − 1.81; P < 0.0001) in insulin-naïve participants and − 0.95%-points (− 1.08; − 0.82; P < 0.0001) in insulin-experienced participants. Mean (95% CI) changes in FPG and SMPG were − 2.27 mmol/L (− 2.69; − 1.85; P < 0.0001) and − 2.89 mmol/L (− 3.52; − 2.25; P < 0.0001), respectively, with similar reductions in insulin-naïve and insulin-experienced subgroups. Rate of hypoglycemia did not change statistically significantly from baseline to EOS overall, or in insulin-experienced participants, except when adjusted for baseline hypoglycemia. Basal insulin dose did not change statistically significantly in insulin-experienced participants.ConclusionIn routine clinical practice in China, initiation or switching to degludec was associated with improvements in glycemic control in people with T2D, with no increased risk of hypoglycemia.Trial RegistrationClinialTrials.gov, NCT04227431.

Keywords

China, ConclusionIn routine clinical practice, EOS, HbA1c, HbA1c change, IntroductionInsulin degludec, MethodsThis, ResultsData, Secondary endpoints, T2D, adults, analogues, associated with improvements, audit, basal insulin analogues, basal insulin dose, baseline, baseline hypoglycemia, baseline to EOS, changes, chart review study, clinical practice, control, daily insulin dose, degludec, dose, endpoint, fasting plasma glucose, flexible dosing, glucose, glycated hemoglobin, glycemic control, hemoglobin, hypoglycemia, improvement, initiation, insulin, insulin analogues, insulin degludec, insulin dose, investigate outcomes, non-interventional, outcomes, participants, people, plasma glucose, practice, primary endpoint, rate, rates of hypoglycemia, reduction, retrospective chart review study, review studies, risk, risk of hypoglycemia, routine clinical practice, self-measured plasma glucose, sites, study, subgroups, switching, switching to degludec, type, type 2 diabetes

Funders

  • Novo Nordisk (Denmark)

Data Provider: Digital Science

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+